Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12144256 | 0.94 | HRH3 (0.54) | PYCR1CHRNB2CHRNA4NPSR1ALDH1A1 | |
| SCHEMBL12763726 | 0.90 | CHRNB2 (0.56) | PYCR1CHRNB2CHRNA4ALDH1A1KDM4E | |
| SCHEMBL16312619 | 0.87 | PYCR1 (0.65) | PYCR1NPSR1ALDH1A1KDM4EHRH3 | |
| SCHEMBL12910454 | 0.83 | CHRNB2 (0.50) | PYCR1CHRNB2CHRNA4ALDH1A1KDM4E | |
| SCHEMBL12837021 | 0.81 | HRH3 (0.67) | PYCR1CHRNB2CHRNA4ALDH1A1KDM4E | |
| SCHEMBL12679030 | 0.80 | HRH3 (0.64) | PYCR1NPSR1ALDH1A1KDM4EHRH3 | |
| SCHEMBL23555605 | 0.79 | PYCR1 (0.60) | PYCR1CHRNB2CHRNA4ALDH1A1KDM4E | |
| SCHEMBL171946 | 0.79 | PYCR1 (0.60) | PYCR1CHRNB2CHRNA4ALDH1A1KDM4E | |
| SCHEMBL9513831 | 0.79 | PYCR1 (0.60) | PYCR1CHRNB2CHRNA4ALDH1A1KDM4E | |
| SCHEMBL21078332 | 0.79 | ALDH1A1 (0.56) | CHRNB2CHRNA4ALDH1A1KDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2021124279-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021101919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY | 2021-05-20 | — | — | US | disclosed |
| US-9708305-B2 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives for the treatment of hormone-dependent diseases | UNIVERSITé LAVAL (CA) | 2017-07-18 | — | — | US | disclosed |
| EP-2664619-B1 | Purine derivatives as tools for screening anti-Alzheimer compounds | MANROS THERAPEUTICS (FR) | 2017-07-12 | — | — | EP | disclosed |
| US-20160200685-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | UNIVERSITé LAVAL (CA) | 2016-07-14 | — | — | US | disclosed |
| US-20150299185-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2015-10-22 | — | — | US | disclosed |
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2014-12-11 | — | — | US | disclosed |
| US-8883415-B2 | Aza-benzazolium containing cyanine dyes | Life Technologies Corporation (US) | 2014-11-11 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090281107-A1 | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF THE SAME | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| EP-1727798-B1 | NOVEL ARYL-CONTAINING 5-ACYLINDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | EP | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-7226740-B2 | nucleic acid or a poly(amino acid) samples and dyes in form of staining solution are combined for sufficient time to form dye-analyte complex and are illuminated with an appropriate wavelength whereby nucleic acid or a poly(amino acid) is detected | INVITROGEN CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| WO-2005087726-A1 | NOVEL ARYL-CONTAINING 5-ACYLINDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | WO | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299185-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | LCK, ABL1, TYK2 | PYCR1 1241/4885CHRNB2 4651/4885CHRNA4 4674/4885 |
| US-20090281107-A1 | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF THE SAME | DHFR, DPYD, QDPR | PYCR1 53/4885CHRNB2 2233/4885CHRNA4 1866/4885 |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | PYCR1 786/4885CHRNB2 891/4885CHRNA4 668/4885 |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | IKZF2, RPL6, HNRNPR | PYCR1 3928/4885CHRNB2 4567/4885CHRNA4 4740/4885 |
| US-20160200685-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | STS, SHBG, CYP19A1 | PYCR1 1380/4885CHRNB2 2240/4885CHRNA4 2130/4885 |
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | LCK, TYK2, LTK | PYCR1 1378/4885CHRNB2 4619/4885CHRNA4 4746/4885 |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | CCNI, MKI67, CCNA1 | PYCR1 405/4885CHRNB2 3259/4885CHRNA4 3132/4885 |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | IKZF2, RPL6, HNRNPR | PYCR1 3928/4885CHRNB2 4567/4885CHRNA4 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.